Viewing Study NCT05320159


Ignite Creation Date: 2025-12-24 @ 2:34 PM
Ignite Modification Date: 2026-01-01 @ 6:49 PM
Study NCT ID: NCT05320159
Status: COMPLETED
Last Update Posted: 2022-07-01
First Post: 2022-03-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
Sponsor: Novartis Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module